Myricx Pharma Limited
- Company number
- 12082645
- Status
- Active
- Type
- Ltd
- Incorporated
- 3 Jul 2019
- Nature of business
- Research and experimental development on biotechnology
Registered office
Officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| PUNWANI, Jayson, Dr | Director | 10 Nov 2025 | 28 Aug 2026 |
| RAWAT, Mohit | Director | 3 Oct 2025 | 28 Aug 2026 |
| PENNSEC LIMITED | Corporate-Secretary | 11 Feb 2025 | 28 Aug 2026 |
| BAUER, Michael Karl | Director | 28 Jun 2024 | 28 Aug 2026 |
| MARTIN, Christopher John, Dr | Director | 10 Nov 2023 | 28 Aug 2026 |
| TOBIN, Jonathan Leslie | Director | 19 Apr 2023 | 28 Aug 2026 |
| BHAMAN, Maina | Director | 30 Oct 2019 | 28 Aug 2026 |
| GUPTA, Sandep | Director | 28 Aug 2026 | |
| CULLEN, Richard Samuel | Secretary | 28 Aug 2026 | |
| BUGNON, Bertrand Richard Rene | Director | 28 Aug 2026 | |
| KAHLSTROEM, Johan Mikael Olof | Director | 28 Aug 2026 |
Control
| Name | Nature of control | Notified | Ceased |
|---|---|---|---|
| Professor Edward William Tate | Ownership Of Shares 50 To 75 Percent Voting Rights 50 To 75 Percent Right To Appoint And Remove Directors |
3 Jul 2019 | 30 Oct 2019 |
| Novartis Ag | Ownership Of Shares 75 To 100 Percent Voting Rights 75 To 100 Percent Right To Appoint And Remove Directors |
28 Aug 2026 |
Accounts
| Year ended | Net assets | Cash | Employees |
|---|---|---|---|
| 31 Jul 2025 | - | - | - |
| 31 Jul 2024 | - | - | - |
| 31 Jul 2023 | -£3,684,834 | £985,106 | 6 |
| 31 Jul 2022 | -£1,195,085 | £1,526,888 | 5 |
| 31 Jul 2021 | £1,415,313 | £884,571 | 4 |
| 31 Jul 2020 | £1,753,501 | £1,570,643 | 4 |
Connections
Companies at the same address
- Novartis Europharm Limited (03068306)
- Novartis Grimsby Limited (00170180)
- Novartis Pharmaceuticals UK Limited (00119006)
- Novartis UK Limited (00398071)